AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration

AMAG Pharmaceuticals (NASDAQ:AMAG) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide, which AMAG in-licensed from Palatin Technologies in February 2017.

As quoted in the press release:

“Today’s NDA submission represents a continuation of AMAG’s commitment to support patients with unmet medical needs, and in particular it underscores our commitment to women’s health,” said Julie Krop, M.D., chief medical officer and executive vice president of clinical development and regulatory affairs at AMAG. “We are excited by the prospect of introducing a new treatment option to premenopausal women who suffer from HSDD.”

Click here to read the full press release.